Neurocrine, Mitsubishi Tanabe to develop VMAT2 inhibitor NBI-98854 for movement disorders
Initially, the Japanese firm will develop NBI-98854 in Japan for the chorea associated with Huntington’s disease (HD) and tardive dyskinesia. Complete commercial rights to NBI-98854 in North America,